右美托咪定对心肺转流下冠状动脉旁路移植术后心脏同步化运动的影响

目的 探讨右美托咪定对心肺转流(CPB)下行冠状动脉旁路移植术(CABG)患者心脏同步化运动的影响.方法 择期CPB下行CABG患者24例,年龄43～75岁,体表面积1.53～2.00m2,ASAⅡ或Ⅲ级,心功能Ⅱ或Ⅲ级.采用随机数字表法分为两组:右美托咪定组(D组)和对照组(C组),每组12例.两组术中麻醉维持均采用全凭静脉麻醉,D组于主动脉开放后经微量注射泵静注右美托咪定负荷剂量0.5μg/kg(10 min内注射完),然后以0.5 μg·kg-1·h-1维持给药至术毕,C组静注等量生理盐水.分别于开胸前(T1)和CPB停机后30 min(T2)、60 min(T3)记录血流动力学指标:HR、MAP、CVP、心脏指数(CI),左右心室收缩功能指标:左室射血分数(LVEF)、右室射血分数(RVEF)和心脏同步性参数:PR间期、QRS时限、室间机械延迟(IVMD).结果 与T1时比较,T2、T3时两组HR明显增快、CI明显升高(P＜0.01);与C组比较,D组T2、T3时PR间期明显延长(P＜0.05).两组间QRS时限及IVMD差异无统计学意义.结论 CPB下冠状动脉旁路移植术患者,右美托咪定负荷剂量0.5μg/kg后以0.5μg· kg-1·h-1维持能够延长PR间期,影响房室间同步化运动,但对左右心室间电机械同步化运动无明显影响.     

右美托咪定对老年患者冠状动脉旁路移植术后认知功能的影响

目的 观察右美托咪定对老年患者冠状动脉旁路移植术(coronary artery bypass graft,CABG)后认知功能的影响. 方法 择期行CABG的老年患者60例,年龄60岁～70岁,美国麻醉医师协会(ASA)分级Ⅱ或Ⅲ级,采用随机数字表法分为两组,右美托咪定组(D组)和生理盐水对照组(C组),每组30例.D组患者于麻醉诱导前静脉注射右美托咪定0.6 μg/kg(15 min),随后以0.2 μg· kg-1·h.速率输注至术毕;C组给予等容量生理盐水;其余麻醉措施两组相同.于麻醉后手术前(T1)、心肺转流(cardiopulmonary bypass,CPB)开始后30 min(T2)、CPB结束后30 min(T3)、术后6(T4)、24 h(T5)测定颈内静脉球部血清肿瘤坏死因子(tumor necrosis factor,TNF)-α、白细胞介素(interlukin,IL)-6水平及S100β蛋白浓度.分别于术前1d及术后第1、4、7天对患者进行简易精神状态量表(mini-mental state examination,MMSE)测验. 结果 T2～T5时,D组血清TNF-α、IL-6水平及S100β蛋白浓度明显低于C组(P＜0.05).与T1比较,T2～T5两组血清TNF-α、IL-6水平及S100β蛋白浓度均明显升高(P＜0.05).D组患者MMSE评分术后第4天[(25.2±1.4)分]、第7天[(26.6±13)分]明显低于术前1 d[(29.3±0.8)分],C组患者MMSE评分术后第4天[(23.2±1.0)分]、第7天[(25.6±1.3)分]也较术前1 d[(29.4±1.0)分]明显降低(P＜0.05).术后第4、7天,术后认知功能障碍(postoperative cognitive dysfunction,POCD)的发生率D组(36.7％、30％)均明显低于C组(46.7％、36.7％)(P＜0.05).结论 右美托咪定可降低CPB下行CABG的老年患者POCD的发生率,其机制可能与抑制炎性反应以及S100β蛋白表达有关.     

右美托咪啶对非体外循环冠状动脉旁路移植术患者心肌损伤的影响

目的 评价右美托咪啶对非体外循环冠状动脉旁路移植术患者心肌损伤的影响.方法 择期非体外循环冠状动脉旁路移植术患者46例,性别不限,ASA分级Ⅱ或Ⅲ级,年龄37～64岁,采用随机数字表法,将其随机分为2组(n=23),两组麻醉诱导及麻醉维持方法相同.右美托眯啶组(D组)于麻醉诱导后持续静脉输注右美托咪啶0.5 μg·kg-1∶h-1至术毕,对照组(C组)给予等容量生理盐水.分别于手术开始、血管吻合完毕、血管吻合完毕后30 min和术毕时记录平均肺动脉压、肺毛细血管楔压;中心静脉压和心输出量,计算每搏指数、左室每搏功指数、右室每搏功指数、周围血管阻力和肺血管阻力.分别于麻醉诱导前、术毕、术后4 h和术后24 h时采集静脉血样,采用ELISA法测定血浆心肌肌钙蛋白Ⅰ浓度.结果 与C组比较,D组术毕时每搏指数和左室每搏功指数升高,血管吻合完毕后30 min和术毕时周围血管阻力降低,术后24 h时血浆cTnI浓度降低(P＜0.05);其余血液动力学指标组间差异无统计学意义(P＞0.05).结论 术中静脉输注右美托咪啶0.5 μg·kg-1·h-1可减轻非体外循环冠状动脉旁路移植术患者心肌损伤.

Abstract：

Objective To evaluate the cardioprotective effect of dexmedetomidine in patients undergoing off-pump coronary artery bypass grafting. Methods Forty-six ASA Ⅱ or Ⅲ patients aged 37-64 yr weighing 54-81 kg undergoing off-pump coronary artery bypass grafting were randomized into 2 groups ( n = 23 each): control group (group C) and dexmedetomidine group (group D) . Dexmedetomidine was infused at 0.5 μg·kg-1·h-1 starting after induction of anesthesia until the end of operation in group D. Radial artery was cannulated and Swan-Ganz catheter placed via right internal jugular vein. HR, MAP, mean pulmonary arterial pressure, pulmonary capilary wedge pressure, central venous pressure, and cardiac output were recorded and stroke volume index, left and right ventricular stroke work index, systemic vascular resistance and pulmonary vascular resistance were calculated at the beginning of operation (T1 ), immediately (T2 ) and at 30 min after reestablishment of coronary blood flow (T3 ) and the end of operation (T4 ) . Venous blood samples were taken before induction of anesthesia (T0 , baseline) , at T4 and 4 h (T5 ) and 24 h (T6 ) after operation for determination of plasma concentration of cardiac troponin I by ELISA. Results Stroke volume index and left ventricular stroke work index were significantly higher at T4 while systemic vascular resistance was lower at T34 in group D than in group C. Plasma cardiac troponin Ⅰ concentration was significantly lower at T6 in group D than in group C. Conclusion Dexmedetomidine infusion at 0.5 μg ·kg-1·h-1 during operation can protect myocardium in patients undergoing off-pump coronary artery bypass grafting.     

右美托咪定对非体外循环冠状动脉旁路移植术后患者认知功能障碍发生的影响

目的 评价右美托咪定对患者非体外循环冠状动脉旁路移植术后患者认知功能障碍发生的影响.方法 择期非体外循环冠状动脉旁路移植术患者58例,性别不限,ASA分级Ⅱ或Ⅲ级,年龄51 ～ 63岁,采用随机数字表法分为2组(n=29):对照组(C组)和右美托咪定组(D组).两组麻醉诱导及麻醉维持方法相同.D组于气管插管后静脉输注右美托咪定负荷剂量1 μg/kg,泵注时间15min,继之以0.5 μg· kg-1·h-1的速率输注至术毕,C组静脉输注等容量生理盐水.于麻醉诱导前24h和术后24、48和72 h时记录患者MMSE评分,判断术后72 h内认知功能障碍的发生情况,记录术中舒芬太尼用量和气管拔管时间.结果 与C组比较,D组术后24和48 h时MMSE评分升高,术后72 h内认知功能障碍发生率降低(P＜0.05),术中舒芬太尼用量和气管拔管时间差异无统计学意义(P＞0.05).结论 右美托咪定可明显降低非体外循环冠状动脉旁路移植术后患者认知功能障碍的发生.     

比较非体外循环冠脉旁路移植术后静脉泵注右美托咪定和丙泊酚的效果

目的比较非体外循环冠脉旁路移植术(off-pump coronary artery bypass grafting,OP-CABG)后静脉泵注右美托咪定和丙泊酚的效果。方法随机将120例行OP-CABG的患者分为2组,各60例。研究组术后静脉泵注右美托咪定0.2～0.5μg/(kg·h),对照组静脉泵注丙泊酚1～3 mg/(kg·h)。2组均持续给药12 h。回顾性分析患者的临床资料。结果 2组患者术后ICU留住时间、机械通气时间及SpO_2、体温、心率、VAS评分、低SBP和5 d内谵妄发生率比较,差异均无统计学意义(P0.05)。研究组患者的睡眠评分优于对照组,差异有统计学意义(P0.05)。结论右美托咪定可显著改善不停跳OP-CABG患者术后的睡眠质量,而且不影响术后镇痛及谵妄的发生率。     

术前应用右美托咪定影响冠状动脉旁路移植术后新发心房颤动的倾向性评分匹配分析

目的 探讨行冠状动脉旁路移植术患者术前应用右美托咪定与地西泮后心房颤动（房颤）发生率的差异。方法 采用回顾性队列研究方法,纳入2020年10月—2021年6月于中国人民解放军北部战区总医院行冠状动脉旁路移植术的患者。通过倾向性评分匹配分析法,比较冠状动脉旁路移植术患者术前应用右美托咪定（右美托咪定组）与地西泮（地西泮组）后房颤发生率。结果 纳入207例患者,其中男150例、女57例,平均年龄（62.02±8.38）岁。术前应用右美托咪定患者53例,术前应用地西泮患者154例。匹配前两组高血压患者占比、吸烟患者占比差异有统计学意义（P<0.05）。按1∶1倾向性匹配后,两组各纳入53例患者,两组数据分布均匀。匹配后,右美托咪定组术后房颤发生率较地西泮组低[9.43%(5/53)vs. 30.19%(16/53),P=0.007]。两组患者住院期间均无死亡,术后主要不良事件无明显差别,且右美托咪定组监护室停留时间[（21.28±2.69）h vs.(22.80±2.56)h,P=0.004]及机械通气时间[（18.53±2.25）h vs.(19.85±2.01)h,P=0.002]...     

右美托咪定对全麻低温心肺转流下冠状动脉旁路移植术围术期的心肌保护作用

目的观察右美托咪定对全麻低温心肺转流(CPB)下冠状动脉旁路移植术患者围术期的心肌保护作用。方法择期行全麻低温CPB下冠状动脉旁路移植术患者80例,男67例,女13例。随机均分为右美托咪定组(A组)和对照组(C组)。在中心静脉置管后,A组静脉泵注右美托咪定4μg·kg-1·h-1持续15min后调节维持剂量0.7μg·kg-1·h-1直到手术结束,C组用同样方案静注等容量生理盐水。记录入室后(T0)、麻醉诱导后(T1)、切皮时(T2)、CPB终止时(T3)和手术结束时(T4)的HR、SBP、DBP和血管活性药物用量。测定T1~T4、术后6h(T5)和术后24h(T6)血浆肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白T(cTnT)、肾上腺素(E)和去甲肾上腺素(NE)浓度。结果与T0时比较,T1时两组HR明显减慢,SBP和DBP明显降低(P0.05)。与T1、T2时比较,T3~T6时两组CK-MB、cTnT、E浓度明显升高(P0.05),T3~T5时A组NE浓度明显下降(P0.05),T6时明显升高(P0.05)。T3~T6时A组CK-MB和cTnT浓度明显低于C组(P0.05)。T3~T5时A组E和NE浓度明显低于C组(P0.05)。两组在围术期均未出现严重不良反应。结论右美托咪定能降低全麻低温CPB下冠状动脉旁路移植术围术期心肌缺血的发生,达到围术期心肌保护的作用。     

右美托咪定对经皮冠状动脉介入治疗患者氧化应激的影响

目的评价右美托咪定对经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)患者氧化应激的影响。方法选择急性心肌梗死需行急诊PCI患者50例,男39例,女11例,年龄47~79岁,体重45~83kg,ASAⅢ或Ⅳ级,采用随机数字表法将患者分为右美托咪定组(D组)和对照组(C组),每组25例。D组麻醉诱导前30min静脉泵注负荷剂量右美托咪定0.5μg/kg,泵注时间10min,随后持续静脉泵注右美托咪定0.2~1.0μg·kg~(-1)·h~(-1)至术毕;C组采用同样方法静脉泵注等量生理盐水。根据RASS镇静程度评估表,维持RASS评分-2~2分。于麻醉诱导前(T_0)、术毕(T_1)、术后6h(T_2)和24h(T_3)采集颈静脉血4ml,分别进行中性粒细胞(PMN)计数、血清丙二醛(MDA)浓度和超氧化物歧化酶(SOD)活性测定。记录术中低血压、心动过缓和低氧血症等不良反应的发生情况。结果与T_0时比较,T_1~T_3时两组血清PMN计数、MDA浓度均明显升高,血清SOD活性明显降低(P0.01或P0.05);T_1~T_3时D组PMN计数、MDA浓度均明显低于C组,血清SOD活性明显高于C组(P0.05)。两组患者术中低血压、心动过缓和低氧血症的发生率差异无统计学意义。结论持续静脉泵注右美托咪定0.5μg/kg,可以更好地抑制PCI患者的氧化应激反应,有助于减轻心肌缺血-再灌注损伤。     

右美托咪定对冠状动脉旁路移植术患者麻醉诱导期BIS和血流动力学的影响

目的 观察新型α2肾上腺素受体激动剂右美托咪定对冠状动脉旁路移植术(coronary artery bypass grafting,CABG)麻醉诱导期患者脑电双频谱指数(bispectral index,BIS) 及血流动力学的影响.方法 2010年6月11日～7月30日30例择期CABG(年龄50～70岁,ASA ...     

右美托咪啶复合小剂量舒芬太尼对非体外循环冠状动脉旁路移植术患者麻醉诱导期间血液动力学的影响

目的 评价右美托咪啶复合小剂量舒芬太尼对非体外循环冠状动脉旁路移植术患者麻醉诱导期间血液动力学的影响.方法 拟行非体外循环冠状动脉旁路移植术患者75例,性别不限,年龄46～ 72岁,体重59～86 kg,ASA分级Ⅱ级或Ⅲ级,NYHA心功能分级Ⅱ级或Ⅲ级,左室射血分数≥45％.采用随机数字表法,将患者随机分为3组(n=25):右美托咪啶复合小剂量舒芬太尼组(DS组)、小剂量舒芬太尼组(S1组)和大剂量舒芬太尼组(S2组).DS组以60ml/h的速率静脉输注右美托咪啶0.8 μg/kg(溶于15 ml生理盐水中)15 min;S1组和S2组给予等容量生理盐水.麻醉诱导:静脉注射咪达唑仑0.08mg/kg和哌库溴铵0.12 mg/kg;在静脉注射总量1/3的咪达唑仑和总量1/8的哌库溴铵后,DS组、S1组和S2组分别静脉注射舒芬太尼0.5、0.5和0.8 μg/kg(用生理盐水稀释至10 ml),再静脉注射余量的咪达唑仑;当BIS值≤75时,静脉注射余量哌库溴铵;当BIS值≤55时行气管插管,机械通气,维持PETCO2 30～ 35 mm Hg.记录麻醉诱导期间心血管不良事件的发生情况以及药物干预的情况.结果 与S2组比较,S1组高血压和心动过速的发生率升高,S1组和DS组低血压发生率降低,DS组药物干预率降低(P＜0.05);与S1组比较,DS组高血压、低血压和心动过度的发生率降低,心动过缓发生率升高,药物干预率降低(P＜0.05).结论 右美托咪啶(0.8 μg/kg)复合较小剂量舒芬太尼(0.5μg/kg)有利于稳定非体外循环冠状动脉旁路移植术患者麻醉诱导期间的血液动力学.     

冠状动脉旁路移植术患者左心室舒张功能的初步评估

目的 评价冠状动脉旁路移植术（CABG）患者左心室舒张功能（LVDF）.方法 采用经食管超声心动图（TEE）技术观察46例不停跳CABG（OPCABG）患者手术前后LVDF的变化.结果 与术前比较，术后经二尖瓣尖脉冲多普勒血流频谱（TMF）的舒张早期充盈波（E波）和舒张晚期充盈波（A波）流速显著加快（P＜0.01）；E波血流时间积分（VTIE）和A波血流时间积分（VTIA）显著增加（P＜0.05或P＜0.01）；E波减速时间（DT）和加速时间（AT）显著缩短（P＜0.05或P＜0.01）；而E/A、A波间期和舒张早期充盈分数（RFF）值差异无统计学意义.术后经左上肺静脉血流频谱（PVF）的S、D和AR波的流速显著加快（P＜0.01）；而S/D、AR波间期和AR-A（AR波间期与A波间期之差）差异无统计学意义.面积减少分数（FAC）和心排血量（CO）显著增加（P＜0.01）.PCWP与AR波直线回归方程：PCWP=2.6＋0.4 AR.结论 CABG患者普遍存在以左心室松弛功能减低为主的舒张功能不全，术后早期收缩功能迅速改善，但舒张功能不全依然存在.TEE可区分心脏的收缩和舒张功能.     

Off-pump coronary artery bypass grafting in patients with significant left ventricular dysfunction

Objective  Off-pump coronary artery bypass grafting (OPCAB) is known to preserve left ventricular function better than conventional coronary artery bypass grafting (CCAB). This study was carried out to investigate the safety, feasibility and efficacy of off-pump coronary artery bypass grafting in patients with significant left ventricular dysfunction. Methods  Three hundred and eighty eight consecutive patients with preoperative left ventricular ejection fraction ≤ 39% who underwent CABG between January 2001 through October 2007 were included in this retrospective study. Two hundred and eleven patients were operated by off-pump technique (group 1) and 178 patients were operated by on-pump technique (CCAB) (group 2). The postoperative outcomes were analyzed. Of these, 204 (52.57%) patients were diabetics, 355 (91.49%) patients had documented prior myocardial infarction, 316 (81.44%) patients were in canadian cardiovascular society(CCS) class III and 47 (12.11%) patients were in CCS class IV. Results  There was no significant difference in the number of grafts per patient between the two groups [group 1 3.02 ± 0.76 vs group 2 3.18 ± 0.72 (P=0.07) and the index of completeness of revascularization was comparable [1.08 ± 0.08) (OPCAB) vs 1.04 ± 0.06 (CCAB) (p=0.52)] The left internal thoracic artery was anastomosed to left anterior descending artery in 98% of patients. Operative mortality was 2.8% (6 deaths) following OPCAB and 3.93% (7 deaths) following CCAB (p=0746). Postoperative usage of IABP support was higher in CCAB group (12 patients vs 4 patients: P<0.03) and usage of moderate or higher doses of inotropic support was also higher in the conventional group (p<0.0006). More worsening of preexisting renal insufficiency was observed in CCAB group (p=0.01) and no significant difference in the incidence of atrial fibrillation was observed between the groups. Conclusions  Off-pump coronary artery bypass grafting is feasible and safe in patients with depressed left ventricular function and the postoperative morbidity was less in OPCAB group compared to on-pump group.     

Mid-term outcomes of coronary artery bypass grafting in patients with mild left ventricular systolic dysfunction: a multicentre retrospective cohort study

 Open in a separate windowOBJECTIVESLeft ventricular systolic dysfunction (LVSD) is common and associated with adverse events in patients receiving coronary artery bypass grafting (CABG). However, the prognosis of mild LVSD has not been clearly described. We aimed to evaluate the mid-term outcomes of patients with mild LVSD following CABG.METHODSThis multicentre cohort study using propensity score matching took place from December 2012 to October 2019 in Jiangsu Province, China, with a mean and maximum follow-up of 3.2 and 7.2 years, respectively. Patients were classified to normal left ventricular systolic function (left ventricular ejection fraction ≥53%) and mild LVSD (left ventricular ejection fraction >40%/<53%). The primary outcomes were death from all causes and death from cardiovascular causes. The secondary outcomes were heart failure, myocardial infarction, repeat revascularization and a composite of all mentioned outcomes, including death from all causes (major adverse events).RESULTSA total of 581 pairs were formed after matching. In-hospital death (1.5% vs 2.1%, P = 0.51) did not differ between 2 cohorts. Throughout 7 years, mild LVSD was associated with higher rates of death from all causes [hazard ratio (HR) 0.59, 95% confidence interval (CI) 0.39–0.89; P = 0.012], death from cardiovascular causes (HR 0.55, 95% CI 0.36–0.90; P = 0.017), heart failure (HR 0.60, 95% CI 0.37–0.93; P = 0.023) and major adverse events (HR 0.66, 95% CI 0.49–0.91; P = 0.009). There was no difference in the rates of myocardial infarction and repeat revascularization.CONCLUSIONSMild LVSD was associated with a worse mid-term prognosis in patients following CABG.     

Long-term survival and functional recovery after isolated coronary artery bypass grafting in patients with severe left ventricular dysfunction

Objective  Coronary artery bypass grafting (CABG) in patients with left ventricular dysfunction has been considered to be a challenging operation. We assessed the early angiographic and long-term clinical and functional outcomes of patients with poor left ventricular function who underwent isolated CABG. Methods  We retrospectively reviewed the records of 78 patients with a poor left ventricular ejection fraction (35% or less) who underwent isolated CABG between January 1991 and November 2006. The mean age of the patients was 66.1 ± 9.4 years, and their mean New York Heart Association functional class was 3.1 ± 0.8. Their mean end-diastolic left ventricular diameter was 57.4 ± 8.1 mm, and their mean grade of mitral regurgitation was 0.7 ± 1.0. Early postoperative angiograms were performed at 32.5 ± 33.5 days after the operation. Interval echocardiographic data were analyzed, and the long-term survival rate was evaluated. Results  The average number of distal anastomoses per patient was 3.2 ± 1.1. The operative mortality rate was 7.7%. Stroke occurred in 1.3% of patients. The overall patency rates for arterial and venous grafts were 100% and 97.2%, respectively. The left ventricular ejection fraction significantly improved from 28.2% ± 5.1% to 34.4% ± 8.4%. Both the end-diastolic and end-systolic left ventricular dimensions significantly decreased from 57.4 ± 8.1 to 55.1 ± 8.8 mm and from 47.4 ± 8.4 to 45.1 ± 9.7 mm, respectively. The actuarial patient survival rate at 10 years was 73.1%. Conclusion  CABG in patients with left ventricular dysfunction was effective, with favorable early graft patency rates. The long-term outcome was also acceptable, with echocardiographic functional recovery.     

七氟烷对体外循环冠状动脉旁路移植术患者左心室功能的影响

目的 评价七氟烷对体外循环(CPB)冠状动脉旁路移植术(CABG)患者左心室功能的影响.方法 择期CPB下行CABG的冠心病患者35例,男性30例,女性5例,年龄53～75岁,身高150～183 cm,体重46～100 kg,AsAⅡ或Ⅲ级,七氟烷分为冠脉搭桥前后2个阶段给药,分别为气管插管后至锯胸骨前和关闭胸腔至手术结束前,CPB期间停止吸入七氟烷.七氟烷呼气末浓度相当于1 MAC.围术期行食管超声心动图(TEE)检查,于锯胸骨前未吸入七氟烷(T_1)、吸入5 min(T_2)、15 min(T_3)、关闭胸腔后未吸入七氟烷(T_4)、吸入5 min(T_5)、15 min(T_6)时记录平均动脉压(MAP)和TEE监测指标:E波、A波、S波.D波和AR波的峰值、心指数(CI)、左室短轴缩短率(FS)、左室射血分数(LVEF),左心室舒张早期血流播散速度(Vp),计算E波与A波峰值比(E/A)、S波与D波峰值比(S/D) 和E波与Vp的比值(E/Vp).结果 与T_1时比较,T_(2,3)时MAP降低,T_3时LVEF、FS和CI降低,T_4时HR、LVEF、FS、CI升高,.E波:A波、S波、D波和AR波的峰值升高(P<0.05或0.01);与T_4时比较,T_(5,6)时MAP降低,T_6时LVEF、FS和CI降低(P<0.05或0.01).结论 呼气末浓度相当于1 MAc的七氟烷可明显抑制CPB下CABG患者左心室收缩功能,但对舒张功能无明显影响.     

组织多普勒成像监测冠状动脉旁路移植术患者左心室功能的可行性

目的采用组织多普勒成像(TDI)技术监测冠状动脉旁路移植前、后左心室前壁心肌组织功能的变化,评价TDI术中监测左心室功能的可行性。方法随机连续选择左前降支冠状动脉旁路移植术患者40例,采用TEE探头在胃底左心室短轴切面取左心室前壁中层行TDI采样,记录收缩速度(Vs)、舒张早期速度(Ve)、舒张晚期速度(Va),并计算Ve/Va;采用TEE二维超声行左室室壁运动视觉评分,测量左心室射血分数(EF)、左心室充盈早期血流速度(E)、晚期速度(A)频谱,并计算E/A;通过肺动脉导管记录心输出量(CO)、肺毛细血管楔压(PCWP)和中心静脉压(CVP)。将TDI技术测定的左心室功能参数分别与TEE二维超声和肺动脉导管测定的参数进行直线相关分析。结果所有患者均可获得满意的左心室前壁中层TDI频谱;冠状动脉旁路移植后左心室前壁Vs、Ve、Va较移植前增加(P<0.05),Ve/Va无明显变化(P>0.05);移植后室壁运动视觉评分改善,EF增加(P<0.05),二尖瓣频谱显示A波增加(P<0.05),E波无明显变化,E/A下降(P<0.01);移植后CO及心指数(CI)增加(P<0.01)。直线相关分析显示左室前壁Vs与CO、CI无相关关系,Ve/Va与CVP、PCWP和二尖瓣血流E/A在移植前、后均无相关关系。TDI未提示患者出现新的心肌缺血证据。结论左心室前壁TDI能定量测定冠状动脉旁路移植前、后局部心肌组织功能的变化,但不能反映左心室整体功能的变化。